Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery

This study has been completed.

Sponsor:

Collaborators:

European Foundation for the Study of Diabetes

Medical University of Graz

Information provided by (Responsible Party):

Bernd Schultes, Cantonal Hospital of St. Gallen

ClinicalTrials.gov Identifier:

NCT01271062

First received: January 5, 2011

Last updated: March 6, 2013

Last verified: March 2013

History of Changes

Purpose

Bariatric operations such as the gastric bypass procedure provide a unique in vivo model of improvement of pathological beta cell function. The presented double-centre study aims to comprehensively investigate different aspects of beta cell function in patients with type 2 diabetes (T2DM) with a wide range of disease duration after gastric bypass. In parallel, our project will address the aspects of changes in enteroinsular and adipoinsular axes as well as the early and late changes of other defined parameters after gastric bypass surgery.

Condition	Intervention
Diabetes Mellitus, Type 2 Bariatric Surgery Candidate	Procedure: gastric bypass surgery Procedure: abdominal surgery Behavioral: very low caloric diet


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science
Official Title:	Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery in Severely Obese Patients With Type 2 Diabetes

Further study details as provided by Bernd Schultes, Cantonal Hospital of St. Gallen:

Primary Outcome Measures:

Acute insulin response (AIR) to glucose during IVGTT will be used as a primary variable characterizing the beta cell function [ Time Frame: 10 days after gastric bypass ]

Secondary Outcome Measures:

OGTT calculations and modelling describing beta cell response to oral glucose load; Insulin and C-peptide areas under the curve (AUCs) during OGTT quantifying the incretin effect. [ Time Frame: 10 days after gastric bypass ]
• Plasma concentrations and adipose tissue expression of selected adipokines and inflammatory cytokines characterizing the adipoinsular axis [ Time Frame: 10 days after gastric bypass ]


Enrollment:	55
Study Start Date:	October 2009
Study Completion Date:	December 2012
Primary Completion Date:	November 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: T2DM patients before gastric bypass surgery oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.	Procedure: gastric bypass surgery
Active Comparator: Non-diabetic patient before gastric bypass surgery oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.	Procedure: gastric bypass surgery
Active Comparator: non diabetic patients, non-bariatric abdominal surgery oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.	Procedure: abdominal surgery
Active Comparator: severely obese T2DM patients following a very low caloric diet oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.	Behavioral: very low caloric diet

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

> 18 years
indication forbariatric surgery or non-bariatric abdominal surgery

Exclusion Criteria:

Pregnancy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01271062

Locations


Austria
Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, MEdical University of Graz, Austria
Graz, Austria, 8036
Switzerland
Interdisciplinary Obesity Center, Kantonal Hospital St. Gallen, Switzerland
St. Gallen, Switzerland, 9400

Sponsors and Collaborators

Cantonal Hospital of St. Gallen

European Foundation for the Study of Diabetes

Medical University of Graz

Investigators


Principal Investigator:	Bernd Schultes, Prof.	Interdisciplinary Obesity Center, Kantonal Hospital St. Gallen, Switerland
Principal Investigator:	Thomas Pieber, Prof.	Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, Medical University of Graz, Austria

More Information


Responsible Party:	Bernd Schultes, Head of Interdisciplinary Obesity Center, Cantonal Hospital of St. Gallen
ClinicalTrials.gov Identifier:	NCT01271062 History of Changes
Other Study ID Numbers:	EKSG 09/061/2B
Study First Received:	January 5, 2011
Last Updated:	March 6, 2013

Keywords provided by Bernd Schultes, Cantonal Hospital of St. Gallen:


Resolvment of Diabetes Mellitus, Type 2 gastric bypass

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases

ClinicalTrials.gov processed this record on July 26, 2017

To Top